Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Inclusion Criteria: * Written informed consent must be obtained before any assessment is performed. * Patients must be diagnosed with relapsing remitting MS (RRMS) as defined by 2005 revised McDonald criteria (McDonald et al 2001, Polman et al 2005) (Appendix 2). * Patients who explicitly agree to be assigned to a treatment group that may receive or DMT after having been informed about their respective benefits and possible adverse events by the investigator. * Male or female patients aged 18-70 years. * An Expanded Disability Status Scale (EDSS) score of 0-6 inclusive. * Must have received continuous treatment with a single approved and indicated MS DMT for a minimum of 6 months prior to the screening visit. Patients must continue with this MS DMT until the randomization visit. * Naïve to treatment with fingolimod. Exclusion Criteria: * A manifestation of MS other than those defined in the inclusion criteria. * A history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome. * History of malignancy of any organ system. * Diagnosis of macular edema during Screening Phase. * Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to have positive HIV antibody test. * Patients who have received any live or live attenuated vaccines (including for varicella-zoster virus or measles) within 2 months prior to baseline. * Patients who have received total lymphoid irradiation or bone marrow transplantation. * History of selected immune system treatments and/or medications. * Any medically unstable condition, as assessed by the investigator. * Selected cardiovascular, or hepatic conditions * Selected abnormal laboratory values. * Patients with any other disease or clinical condition (including neurologic or psychiatric disorders) which may affect patient enrollment into the study and study medication use by the Investigators' opinion. * Participation in any clinical research study evaluating another not approved in Russia investigational drug or therapy within 6 months prior to baseline. * History of hypersensitivity to the study drug or to drugs of similar chemical classes. * Pregnant or nursing (lactating) women. Other protocol-defined inclusion/exclusion criteria may apply